Friday's Sales Include Amcor, Tapestry, and Coherent
Some of the luxury goods companies are suffering from tariffs. Tapestry(TPR) lost 15.71% to close at $95.69 on August 14. This is a sell-off not seen in five years. The supplier of Kate Spade products posted revenue growth of 8.2% Y/Y to $1.72 billion. The outlook disappointed investors.Tapestry blamed a slow turnaround for the pressures ahead. Its CEO said the firm needs a strategic and financial “reset” to achieve long-term growth. Profit and revenue pressures will continue this year.The company reported an unadjusted loss of $517 million. It earned $159.3 million last year.Amcor (AMCR) lost 11.87% on Thursday to close at $8.76. It recorded revenue of $5.08 billion (+43.5% Y/Y). However, the business faces weaknesses in markets that should demonstrate growth. North America is also a weaker environment, hurt by overall consumer sentiment. Consumers seek value amid tougher market conditions.Investors should consider a position in this packaging supplier.Coherent (COHR) lost nearly 20% of its value to close at $91.65. Shares traded at a premium during the sell-off. At a forward P/E of 24.8 times, investors disliked the first-quarter outlook. EPS is up to $1.13 and as low as $0.93. The photonics leader is attractive if the stock price falls by another 10%. Still, bargain hunters might buy the stock before that happens.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


